A brain stem glioma is a tumor in the brain stem that arises from the glial cells of the brain. These tumors normally start in the brain or spinal cord and can spread throughout the nervous system, but do not frequently enter the rest of the body. Brain stem gliomas typically are found in the pons, and more frequently arise from the left side of the brain. The causes of brain stem gliomas are still not known, and there have not been any direct genes related to this disorder. Symptoms of brain stem gliomas include double vision, weakness, seizures, headaches and issues with balance. It is difficult to treat brain stem gliomas with surgery due to their location near vital components of the brain. Therefore, chemotherapy and radiation therapy are used as the most common treatments. Brain stem gliomas are very aggressive and malignant, resulting in a three year survival rate of only 13%.
Brain Stem Glioma Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Brain Stem Glioma below!
For more information on how to use Laverne, please read the How to Guide.
We have 2106 products for the study of Brain Stem Glioma that can be applied to Chromatin Immunoprecipitation, Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Chromatin Immunoprecipitation (ChIP), Immunohistochemistry from our catalog of antibodies and ELISA kits.
Brain Stem Glioma is also known as Brainstem Glioma, Glioma Of Brain Stem, Glioma Of The Brain Stem, Glioma Of The Brainstem.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.